viduals were resistant to at least 10,000 x this concentration during the same incubation period. Further studies have confirmed this initial finding of differential sensitivity of CLL lymphocytes (Thomson et al., 1972; Schrek et al., 1976) . Colchicine ultrasensitive (CUS) lymphocytes have also been reported in the peripheral blood of 9/23 patients with lymphoproliferative disease other than CLL (Thomson et al., 1974) . They studied a heterogeneous group of patients with non-Hodgkin's lymphoma (NHDL), macroglobulinaemia or unexplained lymphocytosis. Thomson's report (1974) prompted our group in 1975 to use colchicine ultrasensitivity in addition to cell-surface markers to study early blood involvement of patients with NHDL. In a preliminary report of this work, 20/51 patients with NHDL had circulating CUS lymphocytes (Scarffe et al., 1977) . All the patients with CUS lymphocytes had lymphocyte counts below 7 x 109/1. Schrek et al. (1978) found CUS lymphocytes in the peripheral blood of 10/13 patients with NHDL. Four of these patients, however, had lymphocyte counts greater than 7 x 109/1 and two more had circulating large morphologically abnormal cells.
There were four main aims to this study. The first was to confirm the colchicine ultrasensitivity of CLL lymphocytes. The second was to confirm the presence of CUS lymphocytes in the peripheral blood of patients with NHDL, looking specifically at those patients with normal lymphocyte morphology and count ( < 5 x 109/1). The third was to determine whether the apparently normal lymphocytes which were CUS represented a population of circulating malignant lymphoid cells, using surface-marker studies, and investigation of tissues from lymph nodes, spleens and marrows involved with NHDL. The Lymphnode biopsies from patients with NHDL were reviewed and classified according to Rappaport (1966) . Patients were staged using the Ann Arbor classification for Hodgkin's disease (Carbone et al., 1971) . Staging laparotomies were not performed, but intensive staging techniques including marrow aspirate and trephines, percutaneous liver biopsies, cerebrospinal fluid examination, and abdominal lymphography were all used as indicated.
All patients with NHDL were studied before treatment. Six of the 20 patients with CLL had been treated previously. In these patients the studies were carried out when the treatment had been stopped for at least 3 months. Materials and methods.-Lymphocyte preparations from lymphnode and spleen samples were obtained by gentle teasing and disaggregation with forceps and scissors. Lymphocyte preparations were assessed for viability by Trypan-blue exclusion. Preparations containing less than 9000 viable cells were not tested with colchicine. Lymphocytes were separated from defibrinated peripheral blood, and heparinized marrow samples using a Ficoll-Triosil density gradient. PBL from 2 normal controls were separated further into T-rich and B-rich populations by a rosetting technique (Wybran et al., 1973) . The technique for testing colchicine ultrasensitivity (CUS) was similar to that described by Thomson et al. (1972) . The lymphocytes obtained were washed and suspended in tissue-culture Medium 199 (Burroughs Wellcome) at a concentration of 1*5 x 106/ml with 30% autologous serum.
Seven 0-5ml aliquots of the suspension were incubated for 24 h in 5% CO2 at 37TC.
Colchicine (Koch-Light) was added at the start of the incubation period to 6 of the aliquots to give final concentrations ranging from 10-2 to 10-7 molar. The seventh aliquot acted as a control.
The number of cells killed was determined by assessing the percentage showing nuclear pyknosis in a smear wet-fixed in Susa and stained with Mayer's haemalum (Trowell, 1952 (Trowell, , 1955 . Five hundred cells were assessed in each aliquot.
Lymphocyte surface-marker studies were performed and assessed as described previously (Garrett et al., 1979) .
Marrow aspirates were examined for the number of lymphocytes and the presence of any immature cells. The upper limit of normal for lymphocytes was taken as 20% of the nucleated cells; 20-25% lymphocytes was considered equivocal, and 25% or over evidence of infiltration. If there were more than 5% abnormal immature lymphocytes, this was also taken as evidence of marrow involvement. The marrow trephine was considered to be involved if there was a significant diffuse, paratrabecular or focal infiltration of lymphocytes.
Statistical analysis. Each patient or control studied gave a 7-point curve for cell death .594
(nuclear pyknosis). To reduce the complexity of comparing over 200 7-point pyknosis curves, a principal-components analysis was performed (Kendal, 1975 chicine). The marked difference in CUS between CLL cells and normal lymphocytes was clearly demonstrated. Scattergrams of the 1st and 2nd components showed no difference between the healthy normal controls and the patients with medical conditions other than CLL or lymphoma; they are therefore shown together in Fig. 2 . Any figure for the first component greater than the percentile of the results obtained from the 84 controls (i.e. > 0.62) was considered positive for the presence of CUS cells. The first component increases with increasing percentage of pyknotic cells at low concentrations of colchicine. In the examples shown in Fig. 1 , the values for the first component of the pyknosis curves of the normal and CLL patients were -2, and 4. Two results in the control group were greater than the 97-5 percentile limit of 0-62 for the first component, with values of 0-7 and 0-97. The first was a healthy 18-year-old technician whose test result was normal on two further occasions. The second was a boy 4 years old who developed acute lymphoblastic leukaemia 6 months later. At the time of the test he had a nonspecific illness, with only 1% blast cells in the marrow. (Fig. 3) . Lymphnode biopsies were studied in 6 of these patients, and the lymphocytes were CUS in 5. Lymphocytes from one involved marrow were studied, and these were also CUS.
One patient was found to have cells resistant to colchicine in both the peripheral blood and in an involved lymph node. This patient's PBL had originally shown CUS, but as his disease progressed, with an increasing lymphocytosis, the percentage of ultrasensitive cells decreased, although the absolute number remained the same. This change in CUS was not paralleled by a change in surface markers. IgG A surface immunoglobulin was demonstrated on 80-90% PBL at all times, and also from the lymphnode biopsy specimen. To ascertain the accuracy of colchicine ultrasensitivity in detecting circulating abnormal lymphocytes, a mixing experiment was performed in which lymphocytes from a CLL donor were mixed in an increasing proportion with lymphocytes from a normal donor and incubated under the standard conditions with 10-6M colchicine. The percentage of pyknotic cells reflected accurately the percentage of CLL cells in the mixture after correction had been made for the number of pyknotic cells in the normal lymphocyte population, and for the resistant lymphocytes in the CLL population at each concentration of cells (Fig. 4) .
Non-Hodgkin's lymphorna patients CUS lymphocytes were detected in 23 (77%o) of the 30 samples of histologically involved lymph nodes, marrows or spleens from patients with NHDL (Table I) Fig. 1 shows a lymphocyte preparation from a patient with NHDL in which 45%o of the cell population was pyknotic at low concentrations of colchicine, the remainder becoming pyknotic only at 10-2M colchicine. Two populations of lymphocytes were present; one ultrasensitive to small doses of colchicine similar to CLL lymphocytes, and another similar to the normal control lymphocytes. The first principal component of the pyknosis curve was 1-2.
PBL from 75 NHDL patients were studied for CUS. All the patients had PBL counts below 5 x 109/1 and the lymphocytes appeared normal by light microscopy. Twenty-four (32%) of the patients were found to have circulating CUS cells patients whose lymphnode histol classified as diffuse histiocyti( (Table II) .
There was a good correlation the presence of circulating mono( lymphocytes and CUS cells in patients with NHDL in whom boti were performed (Table IV) . (Schrek, 1974) . No difference in response was found between those patients with CUS and those without.
Five Stage I and II patients with peripheral-blood involvement (Table II) were analysed for signs of early dissemination over a follow-up of 1-3 years. All the patients are alive and well; one patient with NLPD lymphoma quickly relapsed in the marrow, the 4 other patients remain well without any sign of disease, but 3 received chemotherapy as an adjunct to radiotherapy.
DISCUSSION
The results in this study confirm the ne ultra-findings of Thomson et al. (1972) The difference between the CUS of CLL eater than lymphocytes which are predominantly B cells and normal cells which are predominantly T cells is not a simple preferential killing of B cells. In the T-and B-,py was cell enrichment experiment, even when the CUS there were 50 and 60% B cells the 1st h node, principal component of the pyknosis curve patients fell well within the normal range.
The presence of a high proportion of CUS cells in 77% of tissue biopsy samples from 30 patients with NHDL is a similar result to that found by Schrek et al. (1978) . They reported that 22 (85%) of 26 lymphnode specimens showed CUS, but only 1/22 reactive nodes studied as controls. The 2 reactive lymph nodes in this study were both resistant to colchicine.
About one-third of the 75 patients with NHDL whose lymphocyte count was below 5 x 109/1 were shown to have circulating CUS cells. These circulating CUS cells are likely to be malignant for three reasons. First, the CUS cells were more commonly found in patients with marrow infiltration in whom blood involvement might be expected. Marrow involvement is the usual precursor to involvement of blood with morphologically abnormal cells. Secondly, a high proportion of cells from involved lymph nodes, spleens and marrows were CUS. The third piece of evidence for the CUS cells being malignant is the close correlation with the presence of a monoclone of B lymphocytes demonstrated by surface marker studies. There were, however, 3/10 patients whose PBL contained a monoclone but whose lymphocytes were not CUS. This is, perhaps, what one would expect, since 20% of lymphoma tissue biopsy samples were not CUS. When cells from these resistant tumours migrate into the peripheral blood they may be detectable by surface marker studies but not by colchicine ultrasensitivity.
The ratio of kappa (K) to lambda (A) light-chain-containing surface Ig was used to determine the presence of a monoclone of B lymphocytes. In most patients the normal lymphocytes were only partially replaced by the monoclonal cells. This mixture of normal and abnormal cells made it impossible to quantitate the absolute number of monoclonal cells to compare with the number of CUS cells present, and to detect very early blood involvement. Circulating CUS cells were detected in one patient with a DLWD lymphoma, in whom a monoclone of lymphocytes was not detected (Table IV ).
An equal number of K-and A-staining cells were detected, indicating a slight increase in A-staining cells but not in sufficient number to fulfill the criteria for a A monoclone of twice as many A-as K-staining cells. The normal lymphocytes were probably masking the presence of a monoclone, but the abnormal cells were clearly detected by CUS.
A recent study demonstrated a monoclone of circulating B lymphocytes in 25/50 patients with NHDL, using surface markers (Garrett et al., 1979) . The presence of a monoclone was shown to be closely associated with marrow infiltration. More patients were found to have abnormal circulating cells in the surfacemarker study than in the present study for two reasons. All lymphoma cells are not CUS, and the upper limit for lymphocyte count was higher at 6 x 109/1 in the surface-marker study. Ault (1979) has confirmed this finding, using a flow cytofluorometric method to detect small numbers of unsuspected monoclonal B lymphocytes in the blood of 11/25 lymphoma patients with morphologically normal circulating lymphocytes.
Circulating CUS cells were detected in all the major histopathological groups of NHDL. They were most commonly detected in DLWD lymphomas, less often in DLPD lymphomas and rarely in DH lymphoma. This could either be because some groups are less CUS or that circulating malignant lymphocytes are less common.
In this series all 6 biopsy samples of lymphoid tissue from patients with DLWD lymphoma and 10/13 biopsy samples from patients with a DLPD lymphoma were CUS. Unfortunately only 2 lymph nodes with a DH pattern were studied, one of which was CUS. Schrek et al. (1978) were able to test 7 lymph nodes involved with a DH lymphoma, 5 of which contained CUS cells. Thus it appears that there were no major differences in colchicine sensitivity of tissue biopsy specimens between the different histopathological groups, and if the cells are present in the peripheral r'l99 blood in sufficient numbers they should be detected by colchicine ultrasensitivity.
There was a statistically significant correlation between the presence of circulating CUS cells and marrow infiltration (P = <0.05) in the 75 patients studied. The frequency of marrow infiltration, however, varied greatly between the different histopathological groups. Infiltration was found in 7/11 patients with DLWD lymphoma, 6/25 patients with DLPD lymphoma but only 2/12 patients with DH lymphoma. Although the numbers are small they reflect the relative frequency of marrow infiltration reported in a larger series (Rosenberg, 1975 The case of the child who later developed acute lymphoblastic leukaemia (ALL) is interesting, since 9/11 patients with ALL whose peripheral blood lymphoblasts have been tested showed ultrasensitivity to colchicine (Scarffe, in preparation) . If circulating CUS cells can be detected in ALL patients with minimal marrow infiltration this could be used to detect early relapse.
The reason that malignant cells from patients with CLL or NHDL are ultrasensitive to colchicine is unknown. No difference has been found in the uptake of colchicine by normal and CLL lymphocytes (Thomson et al., 1972) . CLL cells also demonstrate ultrasensitivity to the Vinca alkaloids which have similar biological actions to colchicine, in that they will bind to microtubules and cause metaphase arrest (Schrek, 1974) . A difference between the microtubules of normal and malignant lymphocytes may therefore explain the differential sensitivity to colchicine. A difference in tubulin has recently been shown using antitubulin antibodies. A "nucleus-associated tubulincontaining structure" was found in virtually all lymphocytes from normal subjects, but in a considerably lower number of CLL lymphocytes (Dighiero et al., 1978) . This hypothesis of the mode of action of colchicine, however, does not explain the finding that the ionophore A23187, which causes uptake into the cell of calcium and other divalent ions, induces resistance to colchicine and vincristine (Schrek et al., 1978) .
Further studies are required to evaluate ultrasensitivity as an aid to diagnosis and staging of NHDL patients. Preliminary studies have shown that colchicine ultrasensitivity may be useful in distinguishing between lymph nodes involved with NHDL and those which show a reactive histological pattern. It has also been suggested that colchicine ultrasensitivity may be useful in deciding whether an anaplastic tumour is of epithelial or lymphoid origin (Schrek et al., 1978 
